Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Once-daily versus twice-daily aspirin dosing for platelet inhibition in stable cardiovascular disease
NL-OMON42162Suspended
- Sponsor
- Amsterdam UMC, location VUmc
- Start
- Jun 2015
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Randomised, single-blind trial of aspirin in cardiac morbidity, coronary arteriosclerosis, peripheral artery occlusion (PAD) and 2 more (3 arms), sponsored by Amsterdam UMC, location VUmc. Primary endpoints: PFA-200 parameters, Chrono-log light transmission aggregometry and 2 more. Started Jun 2015; status: suspended.
02
Drugs
aspirin
03
Conditions
cardiac morbiditycoronary arteriosclerosisperipheral artery occlusion (PAD)myocardial infarction (MI)angina pectoris
Beyond the preview
Go deeper on NL-OMON42162.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON42162.